Redirecting you to external site in 3 seconds : https://news.bms.com/news/corporate-financial/2024/New-Four-Year-Sotyktu-deucravacitinib-Data-Demonstrate-Durable-Response-Rates-and-Consistent-Safety-in-Moderate-to-Severe-Plaque-Psoriasis/default.aspx
If you are not automatically redirected, please